# A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets

> **NCT03196531** · PHASE1 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 108 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Loratadine (Xisimin [Test Treatment])
- **DRUG:** Loratadine (Clarityne [Reference Treatment])

## Key facts

- **NCT ID:** NCT03196531
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-07
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-03-31
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03196531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03196531, "A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03196531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*